• Arrowhead posted prepared remarks from its fiscal 2026 third-quarter conference call attended by CEO Dr. Chris Anzalone, SVP Andy Davis, CMO Dr. James Hamilton, CFO Dan Apel.
• Management highlighted Phase 3 SHASTA-3 and SHASTA-4 topline results in severe hypertriglyceridemia: median triglycerides down 79% and 81% at month 12.
• Pooled analysis showed acute pancreatitis events down 78% versus placebo; highest-risk subgroup showed a 100% reduction, with no new safety signals reported.
• Arrowhead bought an FDA priority review voucher for USD 215 million to target a 6-month review; sNDA submission planned before end-2026.
• REDEMPLO FCS launch: prescriptions more than doubled quarter-on-quarter; commercial revenue about USD 2.4 million; cash and investments USD 1.6 billion at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.